Author(s): DE VELASCO, GUILLERMO ; GRAY, KATHRYN P. ; HAMIEH, LANA ; URUN, YUKSEL ; CAROL, HALLIE A. ; André Poisl Fay ; SIGNORETTI, SABINA ; KWIATKOWSKI, DAVID J. ; MCDERMOTT, DAVID F. ; FREEDMAN, MATTHEW ; POMERANTZ, MARK M. ; CHOUEIRI, TONI K.
Date: 2022
Persistent ID: https://hdl.handle.net/10923/21645
Origin: Oasisbr
Submitted by Biblioteca Suporte PUCRS (biblioteca.suporte@pucrs.br) on 2022-05-17T14:47:58Z No. of bitstreams: 2 Pharmacogenomic_Markers_of_Targeted_Therapy_Toxicity_in_Patients_with_Metastatic_Renal_Cell_Carcinoma.pdf: 221047 bytes, checksum: 78a0cb4619d79956bb22a62fa62575ee (MD5) Pharmacogenomic_Markers_of_Targeted_Therapy_Toxicity_in_Patients_with_Metastatic_Renal_Cell_Carcinoma.pdf: 221047 bytes, checksum: 78a0cb4619d79956bb22a62fa62575ee (MD5)
Made available in DSpace on 2022-05-17T14:47:58Z (GMT). No. of bitstreams: 2 Pharmacogenomic_Markers_of_Targeted_Therapy_Toxicity_in_Patients_with_Metastatic_Renal_Cell_Carcinoma.pdf: 221047 bytes, checksum: 78a0cb4619d79956bb22a62fa62575ee (MD5) Pharmacogenomic_Markers_of_Targeted_Therapy_Toxicity_in_Patients_with_Metastatic_Renal_Cell_Carcinoma.pdf: 221047 bytes, checksum: 78a0cb4619d79956bb22a62fa62575ee (MD5) Previous issue date: 2016
